ClinicalTrials.gg
CompletedNCT02227693Updated Feb 28, 2019Results posted

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia

A Phase 2 interventional study of avatrombopag and Placebo in Thrombocytopenia Associated With Chronic Liver Disease, sponsored by Eisai Co., Ltd.. Completed at 14 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-02-28.

Sponsored by Eisai Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing avatrombopag in Thrombocytopenia — 6 open to participants now, 6 under way, 2 of them phase 3. avatrombopag · Thrombocytopenia.

Enrollment
15th of 23
39 · median 50
Started
2014
with 1 other
Phase 2
10 of 23
3 open now
Registered
6th of 23
by date
Lead sponsor
1 of 23
Eisai Co., Ltd.

Among the 23 studies testing avatrombopag in Thrombocytopenia, this one is the 15th largest by enrollment, is one of 2 that started in 2014, is one of 10 in phase 2, and was the 6th registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

6 of the 23 studies testing avatrombopag in Thrombocytopenia are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About avatrombopag

avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing avatrombopag in Thrombocytopenia, or all of them as a file.
02

Study summary

This is a phase 2, randomized, double-blind, placebo-controlled, parallel group study using avatrombopag for Japanese subjects with thrombocytopenia associated with chronic liver disease. This study will assess the effect of avatrombopag on platelet counts in Japanese subjects. Subjects will be enrolled into 2 cohorts according to the mean platelet count measured at Screening and Baseline. Within the lower baseline platelet count cohort (less than 40 x 10\^9/L), subjects will be randomized in a 1:1:1:3 ratio to receive placebo, 20 mg avatrombopag, 40 mg avatrombopag, or 60 mg avatrombopag for 5 days. Within the higher baseline platelet count cohort (from 40 to less than 50 x 10\^9/L), subjects will be randomized in a 2:1:2 ratio to receive placebo, 20 mg avatrombopag, or 40 mg avatrombopag for 5 days.

Read the detailed description

This study will consist of Prerandomization Phase and Randomization Phase. The Prerandomization Phase includes a Screening Period (Day -28 to Day -1) and a Baseline Period (Day 1). During the Prerandomization Phase, participants will be divided into two cohorts based on the platelet count: Low Platelet Count Cohort and High Platelet Count Cohort. Participants in Low Platelet Count Cohort will be randomized to receive one of the four treatments: Placebo, Avatrombopag 20 mg, Avatrombopag 40 mg, or Avatrombopag 60 mg. Participants in High Platelet Count Cohort will be randomized to receive one of the three treatments: Placebo, Avatrombopag 20 mg, or Avatrombopag 40 mg.

The Randomization Phase includes the Treatment Period and the Follow-up Period. The Follow-up Period comprises 3 visits: Visit 4 (5 to 8 days after last dose of study drug [Study Day 10 to 13]), Visit 5 (12 to 15 days after last dose of study drug [Study Day 17 to 20]), and 30 days after receiving the last dose of study drug.

03

Conditions studied

  • Thrombocytopenia Associated With Chronic Liver Disease

Browse trials for

Keywords

  • Thrombocytopenia
  • Chronic Liver Disease
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Japanese subjects greater than or equal to 20 years of age at Screening with chronic liver disease.
  2. Subjects who have a mean baseline count of less than 50 x 10\^9/L. Platelet counts will be measured on 2 separate occasions, during the Screening Period and at Baseline, and must be performed at least one day apart with neither platelet count greater than 60 x 10\^9/L.
  3. Model For End-stage Liver Disease (MELD) score 24 at Screening.
  4. If taking inhibitors of P glycoprotein (P-gp), except for verapamil, dose must be stable for 7 days prior to Screening.
  5. Provide written .
  6. Willing and able to comply with all aspects of the protocol.

Exclusion criteria

Exclusion Criteria

  1. Any history of arterial or venous thrombosis, including partial or complete thrombosis.
  2. Evidence of thrombosis (partial or complete) in the main portal vein, portal vein branches, or any part of the splenic mesenteric system at Screening.
  3. Portal vein blood flow velocity rate less than 10 cm/second at Screening.
  4. Hepatic encephalopathy that cannot be effectively treated.
  5. Subjects with HCC with Barcelona Clinic Liver Cancer (BCLC) staging classification C or D.
  6. transfusion or receipt of blood products containing platelets within 7 days of Screening. However packed red blood cells are permitted.
  7. Heparin, warfarin, nonsteroidal anti-inflammatory drugs (NSAID), aspirin, verapamil, and antiplatelet therapy with ticlopidine or glycoprotein IIb/IIIa antagonists (eg, tirofiban) within 7 days of Screening.
  8. Use of erythropoietin stimulating agents within 7 days of Screening.
  9. Interferon (IFN) use within 14 days of Screening.
  10. Estrogen-containing hormonal or hormone replacement therapy use within 30 days of Screening.
  11. Active infection requiring systemic antibiotic therapy within 7 days of Screening. However, prophylactic use of antibiotics is permitted.
  12. Alcohol abuse, alcohol dependence syndrome, drug abuse, or drug dependence within 6 months of the study start (unless participating in a controlled rehabilitation program) or acute alcoholic hepatitis (chronic alcoholic hepatitis is allowed) within 6 months of the study start.
  13. Known to be positive.
  14. Any acute or active bleeding (eg, gastrointestinal, central nervous system).
  15. Known history of any primary hematologic disorder (eg, immune thrombocytopenic purpura, myelodysplastic syndrome).
  16. Known medical history of genetic prothrombotic syndromes (eg, Factor V Leiden; prothrombin G20210A; ATIII deficiency etc.)
  17. Subjects with a history of significant cardiovascular disease (eg, congestive heart failure Grade III/IV, arrhythmia known to increase the risk of thromboembolic events [eg, atrial fibrillation], coronary artery stent placement, angioplasty, and coronary artery bypass grafting).
  18. Females of who have had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a progesterone only contraceptive implant/injection, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 30 days after study drug discontinuation. If currently abstinent, the subject must agree to use a double barrier method as described above if she becomes sexually active during the study period or for 30 days after study drug discontinuation. All females will be considered to be of childbearing potential unless they are (at least 12 months consecutive amenorrhea in the appropriate age group and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) at least 1 month before dosing.
  19. Females who are lactating or pregnant at Screening or Baseline (as documented by a positive serum beta-human chorionic gonadotropin [B-hCG] test with a minimum sensitivity 25 IU/L or equivalent units of B-hCG). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
  20. Post liver transplant subjects.
  21. Any subject who has previously received avatrombopag.
  22. to avatrombopag maleate or any of its .
  23. levels less than or equal to 8.0 or greater than or equal to 16.0 g/dL at Screening.
  24. White blood cell count less than or equal to 1.5 x 10\^9/L or greater than or equal to 15.0 x 10\^9/L at Screening.
  25. Serum sodium level less than or equal to 130 milliequivalents/L at Screening.
  26. Current including solid tumors and hematologic malignancies (except HCC).
  27. Any history of a medical condition or a concomitant medical condition that, in the opinion of the investigator(s), would compromise the subject's ability to safely complete the study.
  28. Currently enrolled in another clinical trial or used any drug or device within 30 days of Screening.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    avatrombopag 20-mg

    20 mg avatrombopag (1 x 20 mg tablet and 2 x 20 mg matching placebo tablets) once daily on Days 1 through 5

    Drug: avatrombopag

  • Experimental
    avatrombopag 40-mg

    40 mg avatrombopag (2 x 20 mg tablets and 1 x 20 mg matching placebo tablet) once daily on Days 1 through 5

    Drug: avatrombopag

  • Experimental
    avatrombopag 60-mg

    60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5

    Drug: avatrombopag

  • Placebo comparator
    placebo l

    Placebo (3 x 20-mg matching placebo tablets) once daily on Days 1 through 5

    Drug: Placebo

Interventions

  • E5501 (avatrombopag) 20-mg tablets

  • DrugPlacebo

    Placebo matching 20-mg tablets

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Platelet Count Greater Than or Equal to 50 x 10^9/L and at Least 20 x 10^9/L Increase From Baseline at Visit 4

    Responders were defined as participants whose platelet count was greater than or equal to 50×10\^9/liter (L) and change from baseline was at least 20×10\^9/L at Visit 4. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis. Two-sided 95% confidence interval (CI) is calculated by Clopper and Pearson method.

    Time frame: Baseline and Visit 4 (Day 10)

Secondary outcomes

  1. Percentage of Participants With Platelet Count Greater Than or Equal to 50 x 10^9/L at Each Visit

    Responders were defined as the participants whose platelet count greater than or equal to 50 x 10\^9/L by visit. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis. Two-sided 95% CI is calculated by Clopper and Pearson method.

    Time frame: Visit 3 (Day 4 or 5), Visit 4 (Day 10), Visit 5 (Day 17) and Visit 6 (Day 35)

  2. Percentage of Participants With Platelet Count Greater Than or Equal to 75 x 10^9/L at Each Visit

    Responders were defined as the participants whose platelet count greater than or equal to 75 x 10\^9/L by visit. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis. Two-sided 95% CI is calculated by Clopper and Pearson method.

    Time frame: Visit 3 (Day 4 or 5), Visit 4 (Day 10), Visit 5 (Day 17) and Visit 6 (Day 35)

  3. Percentage of Participants With Platelet Count Greater Than or Equal to 150 x 10^9/L At Each Visit

    Responders were defined as the participants whose platelet count greater than or equal to 150 x 10\^9/L by visit. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis.

    Time frame: Visit 3 (Day 4 or 5), Visit 4 (Day 10), Visit 5 (Day 17) and Visit 6 (Day 35)

  4. Percentage of Participants With Platelet Count Greater Than or Equal to 200 x 10^9/L At Each Visit

    Responders were defined as the participants whose platelet count greater than or equal to 200 x 10\^9/L by visit. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis.

    Time frame: Visit 3 (Day 4 or 5), Visit 4 (Day 10), Visit 5 (Day 17) and Visit 6 (Day 35)

  5. Platelet Count and Change From Baseline in Platelet Count by Visit

    Time frame: Baseline, Visit 3 (Day 4 or 5), Visit 4 (Day 10), Visit 5 (Day 17) and Visit 6 (Day 35)

Other outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Safety assessments consisted of monitoring and recording all AEs and SAEs, regular monitoring of hematology, blood chemistry, and urine values; periodic measurement of vital signs and electrocardiograms; physical examinations; and Doppler sonography. AE severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death related to the AE. All AEs graded as 4 or 5 were considered to be serious. A treatment-emergent adverse event (TEAE) was defined as an AE that started on or after the date of first dose of study drug, up to 30 days after the last dose of study drug. For each category, a participant with two or more adverse events in that category was counted only once. Treatment-related TEAEs were considered by the investigator to be possibly or probably related to study drug or TEAEs with a missing causality.

    Time frame: From the date of first dose of study drug up to 30 days after the last dose of the study drug, up to approximately 10 months

  2. Number of Participants With Treatment-emergent Markedly Abnormal Laboratory Value (TEMAV) for Haematology

    Time frame: From the date of Screening until the date of last dose of study drug plus 30 days (Approximately 10 months)

  3. Number of Participants With Clinically Significant Findings in Laboratory Values for Serum

    Time frame: From the date of Screening until the date of last dose of study drug plus 30 days (Approximately 10 months)

  4. Number of Participants With Clinically Significant Findings in Laboratory Values for Urinalysis

    Time frame: From the date of Screening until the date of last dose of study drug plus 30 days (Approximately 10 months)

  5. Number of Participants With Clinically Significant Change From Baseline in Vital Sign Values

    Time frame: From the date of Screening until the date of last dose of study drug plus 30 days (Approximately 10 months)

  6. Number of Participants With Markedly Abnormal Electrocardiographs

    Time frame: From the date of Screening until the date of last dose of study drug plus 30 days (Approximately 10 months)

07

Results

Posted Feb 28, 2019

Participant flow

Participant flow — Overall Study
MilestonePlacebo (60 mg)Avatrombopag (20 mg)Avatrombopag (40 mg)Avatrombopag (60 mg)
Started1171110
Completed1171110
Not completed0000

Outcome measures

PrimaryPercentage of Participants With Platelet Count Greater Than or Equal to 50 x 10^9/L and at Least 20 x 10^9/L Increase From Baseline at Visit 4

Responders were defined as participants whose platelet count was greater than or equal to 50×10\^9/liter (L) and change from baseline was at least 20×10\^9/L at Visit 4. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis. Two-sided 95% confidence interval (CI) is calculated by Clopper and Pearson method.

Time frame:
Baseline and Visit 4 (Day 10)
Reported as:
Number · Percentage of participants
Percentage of Participants With Platelet Count Greater Than or Equal to 50 x 10^9/L and at Least 20 x 10^9/L Increase From Baseline at Visit 4
Percentage of participantsPlacebo (60 mg)Avatrombopag (20 mg)Avatrombopag (40 mg)Avatrombopag (60 mg)
Percentage of Participants With Platelet Count Greater Than or Equal to 50 x 10^9/L and at Least 20 x 10^9/L Increase From Baseline at Visit 49.1 (0.2 to 41.3)28.6 (3.7 to 71.0)63.6 (30.8 to 89.1)40.0 (12.2 to 73.8)
Statistical analysis
  • Placebo (60 mg) vs Avatrombopag (20 mg) · Shirley-Williams test · p = 0.146 · Difference of responder rate vs. placebo: 19.5 · 95% CI -18.1 to 57.0Difference of responder rate vs. placebo = responder rate for avatrombopag - responder rate for placebo; 95% CI is calculated based on normal approximation.
  • Placebo (60 mg) vs Avatrombopag (40 mg) · Shirley-Williams test · p = 0.004 · Difference of responder rate vs. placebo: 54.5 · 95% CI 21.4 to 87.7Difference of responder rate vs. placebo = responder rate for avatrombopag - responder rate for placebo; 95% CI is calculated based on normal approximation.
  • Placebo (60 mg) vs Avatrombopag (60 mg) · Shirley-Williams test · p = 0.024 · Difference of responder rate vs. placebo: 30.9 · 95% CI -3.9 to 65.7Difference of responder rate vs. placebo = responder rate for avatrombopag - responder rate for placebo; 95% CI is calculated based on normal approximation.
SecondaryPercentage of Participants With Platelet Count Greater Than or Equal to 50 x 10^9/L at Each Visit

Responders were defined as the participants whose platelet count greater than or equal to 50 x 10\^9/L by visit. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis. Two-sided 95% CI is calculated by Clopper and Pearson method.

Time frame:
Visit 3 (Day 4 or 5), Visit 4 (Day 10), Visit 5 (Day 17) and Visit 6 (Day 35)
Reported as:
Number · Percentage of participants
Percentage of Participants With Platelet Count Greater Than or Equal to 50 x 10^9/L at Each Visit
Percentage of participantsPlacebo (60 mg)Avatrombopag (20 mg)Avatrombopag (40 mg)Avatrombopag (60 mg)
Visit 3 (Day 4 or Day 5)0.0 (0.0 to 28.5)14.3 (0.4 to 57.9)27.3 (6.0 to 61.0)0.0 (0.0 to 30.8)
Visit 4 (Day 10)9.1 (0.2 to 41.3)71.4 (29.0 to 96.3)81.8 (48.2 to 97.7)50.0 (18.7 to 81.3)
Visit 5 (Day 17)27.3 (6.0 to 61.0)0.0 (0.0 to 41.0)54.5 (23.4 to 83.3)20.0 (2.5 to 55.6)
Visit 6 (Day 35)18.2 (2.3 to 51.8)0.0 (0.0 to 41.0)9.1 (0.2 to 41.3)0.0 (0.0 to 30.8)
Statistical analysis
  • Placebo (60 mg) vs Avatrombopag (20 mg) · Fisher Exact · p = 0.388 (P-value is based on Fisher's exact test at a two-sided significance level of α = 0.05.) · Difference of proportion vs. placebo: 14.3 · 95% CI -11.6 to 40.2Difference of proportion vs. placebo = proportion of responders for avatrombopag - proportion of responders for placebo; 95% CI is calculated based on normal approximation.
  • Placebo (60 mg) vs Avatrombopag (40 mg) · Fisher Exact · p = 0.214 (P-value is based on Fisher's exact test at a two-sided significance level of α = 0.05.) · Difference of proportion vs. placebo: 27.3 · 95% CI 1.0 to 53.6Difference of proportion vs. placebo = proportion of responders for avatrombopag - proportion of responders for placebo; 95% CI is calculated based on normal approximation.
  • Placebo (60 mg) vs Avatrombopag (20 mg) · Fisher Exact · p = 0.012 (P-value is based on Fisher's exact test at a two-sided significance level of α = 0.05.) · Difference of proportion vs. placebo: 62.3 · 95% CI 24.8 to 99.9Difference of proportion vs. placebo = proportion of responders for avatrombopag - proportion of responders for placebo; 95% CI is calculated based on normal approximation.
  • Placebo (60 mg) vs Avatrombopag (40 mg) · Fisher Exact · p = 0.001 (P-value is based on Fisher's exact test at a two-sided significance level of α = 0.05.) · Difference of proportion vs. placebo: 72.7 · 95% CI 44.3 to 100.0Difference of proportion vs. placebo = proportion of responders for avatrombopag - proportion of responders for placebo; 95% CI is calculated based on normal approximation.
  • Placebo (60 mg) vs Avatrombopag (60 mg) · Fisher Exact · p = 0.063 (P-value is based on Fisher's exact test at a two-sided significance level of α = 0.05.) · Difference of proportion vs. placebo: 40.9 · 95% CI 5.6 to 76.2Difference of proportion vs. placebo = proportion of responders for avatrombopag - proportion of responders for placebo; 95% CI is calculated based on normal approximation.
  • Placebo (60 mg) vs Avatrombopag (20 mg) · Fisher Exact · p = 0.245 (P-value is based on Fisher's exact test at a two-sided significance level of α = 0.05.) · Difference of proportion vs. placebo: -27.3 · 95% CI -53.6 to -1.0Difference of proportion vs. placebo = proportion of responders for avatrombopag - proportion of responders for placebo; 95% CI is calculated based on normal approximation.
  • Placebo (60 mg) vs Avatrombopag (40 mg) · Fisher Exact · p = 0.386 (P-value is based on Fisher's exact test at a two-sided significance level of α = 0.05.) · Difference of proportion vs. placebo: 27.3 · 95% CI -12.2 to 66.8Difference of proportion vs. placebo = proportion of responders for avatrombopag - proportion of responders for placebo; 95% CI is calculated based on normal approximation.
  • Placebo (60 mg) vs Avatrombopag (60 mg) · Fisher Exact · p = 1.000 (P-value is based on Fisher's exact test at a two-sided significance level of α = 0.05.) · Difference of proportion vs. placebo: -7.3 · 95% CI -43.4 to 28.9Difference of proportion vs. placebo = proportion of responders for avatrombopag - proportion of responders for placebo; 95% CI is calculated based on normal approximation.
  • Placebo (60 mg) vs Avatrombopag (20 mg) · Fisher Exact · p = 0.496 (P-value is based on Fisher's exact test at a two-sided significance level of α = 0.05.) · Difference of proportion vs. placebo: -18.2 · 95% CI -41.0 to 4.6Difference of proportion vs. placebo = proportion of responders for avatrombopag - proportion of responders for placebo; 95% CI is calculated based on normal approximation.
  • Placebo (60 mg) vs Avatrombopag (40 mg) · Fisher Exact · p = 1.000 (P-value is based on Fisher's exact test at a two-sided significance level of α = 0.05.) · Difference of proportion vs. placebo: -9.1 · 95% CI -37.5 to 19.3Difference of proportion vs. placebo = proportion of responders for avatrombopag - proportion of responders for placebo; 95% CI is calculated based on normal approximation.
  • Placebo (60 mg) vs Avatrombopag (60 mg) · Fisher Exact · p = 0.476 (P-value is based on Fisher's exact test at a two-sided significance level of α = 0.05.) · Difference of proportion vs. placebo: -18.2 · 95% CI -41.0 to 4.6Difference of proportion vs. placebo = proportion of responders for avatrombopag - proportion of responders for placebo; 95% CI is calculated based on normal approximation.
SecondaryPercentage of Participants With Platelet Count Greater Than or Equal to 75 x 10^9/L at Each Visit

Responders were defined as the participants whose platelet count greater than or equal to 75 x 10\^9/L by visit. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis. Two-sided 95% CI is calculated by Clopper and Pearson method.

Time frame:
Visit 3 (Day 4 or 5), Visit 4 (Day 10), Visit 5 (Day 17) and Visit 6 (Day 35)
Reported as:
Number · Percentage of participants
Percentage of Participants With Platelet Count Greater Than or Equal to 75 x 10^9/L at Each Visit
Percentage of participantsPlacebo (60 mg)Avatrombopag (20 mg)Avatrombopag (40 mg)Avatrombopag (60 mg)
Visit 3 (Day 4 or Day 5)0.0 (0.0 to 28.5)0.0 (0.0 to 41.0)0.0 (0.0 to 28.5)0.0 (0.0 to 30.8)
Visit 4 (Day 10)0.0 (0.0 to 28.5)0.0 (0.0 to 41.0)63.6 (30.8 to 89.1)30.0 (6.7 to 65.2)
Visit 5 (Day 17)0.0 (0.0 to 28.5)0.0 (0.0 to 41.0)0.0 (0.0 to 28.5)10.0 (0.3 to 44.5)
Visit 6 (Day 35)0.0 (0.0 to 28.5)0.0 (0.0 to 41.0)0.0 (0.0 to 28.5)0.0 (0.0 to 30.8)
Statistical analysis
  • Placebo (60 mg) vs Avatrombopag (40 mg) · Fisher Exact · p = 0.003 (P-value is based on Fisher's exact test at a two-sided significance level of α= 0.05.) · Difference of proportion vs. placebo: 63.6 · 95% CI 35.2 to 92.1Difference of proportion vs. placebo = proportion of responders for avatrombopag - proportion of responders for placebo; 95% CI is calculated based on normal approximation.
  • Placebo (60 mg) vs Avatrombopag (60 mg) · Fisher Exact · p = 0.090 (P-value is based on Fisher's exact test at a two-sided significance level of α= 0.05.) · Difference of proportion vs. placebo: 30.0 · 95% CI 1.6 to 58.4Difference of proportion vs. placebo = proportion of responders for avatrombopag - proportion of responders for placebo; 95% CI is calculated based on normal approximation.
  • Placebo (60 mg) vs Avatrombopag (60 mg) · Fisher Exact · p = 0.476 (P-value is based on Fisher's exact test at a two-sided significance level of α= 0.05.) · Difference of proportion vs. placebo: 10.0 · 95% CI -8.6 to 28.6Difference of proportion vs. placebo = proportion of responders for avatrombopag - proportion of responders for placebo; 95% CI is calculated based on normal approximation.
SecondaryPercentage of Participants With Platelet Count Greater Than or Equal to 150 x 10^9/L At Each Visit

Responders were defined as the participants whose platelet count greater than or equal to 150 x 10\^9/L by visit. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis.

Time frame:
Visit 3 (Day 4 or 5), Visit 4 (Day 10), Visit 5 (Day 17) and Visit 6 (Day 35)
Reported as:
Number · Percentage of participants
Percentage of Participants With Platelet Count Greater Than or Equal to 150 x 10^9/L At Each Visit
Percentage of participantsPlacebo (60 mg)Avatrombopag (20 mg)Avatrombopag (40 mg)Avatrombopag (60 mg)
Visit 3 (Day 4 or Day 5)0.00.00.00.0
Visit 4 (Day 10)0.00.00.00.0
Visit 5 (Day 17)0.00.00.00.0
Visit 6 (Day 35)0.00.00.00.0
SecondaryPercentage of Participants With Platelet Count Greater Than or Equal to 200 x 10^9/L At Each Visit

Responders were defined as the participants whose platelet count greater than or equal to 200 x 10\^9/L by visit. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis.

Time frame:
Visit 3 (Day 4 or 5), Visit 4 (Day 10), Visit 5 (Day 17) and Visit 6 (Day 35)
Reported as:
Number · Percentage of participants
Percentage of Participants With Platelet Count Greater Than or Equal to 200 x 10^9/L At Each Visit
Percentage of participantsPlacebo (60 mg)Avatrombopag (20 mg)Avatrombopag (40 mg)Avatrombopag (60 mg)
Visit 3 (Day 4 or Day 5)0.00.00.00.0
Visit 4 (Day 10)0.00.00.00.0
Visit 5 (Day 17)0.00.00.00.0
Visit 6 (Day 35)0.00.00.00.0
SecondaryPlatelet Count and Change From Baseline in Platelet Count by Visit
Time frame:
Baseline, Visit 3 (Day 4 or 5), Visit 4 (Day 10), Visit 5 (Day 17) and Visit 6 (Day 35)
Reported as:
Mean · Number of platelets x 10^9/L
Platelet Count and Change From Baseline in Platelet Count by Visit
Number of platelets x 10^9/LPlacebo (60 mg)Avatrombopag (20 mg)Avatrombopag (40 mg)Avatrombopag (60 mg)
Visit 2 (Baseline) Platelet count40.59 ± 7.02440.57 ± 5.55641.23 ± 5.15928.85 ± 7.568
Visit 3 (Day 4 or Day 5) Platelet count41.27 ± 8.34444.71 ± 6.10246.09 ± 8.86032.70 ± 9.967
Visit 3 (Day 4 or Day 5) Change from baseline0.68 ± 2.8484.14 ± 7.0994.86 ± 6.5693.85 ± 6.223
Visit 4 (Day 10) Platelet count43.91 ± 10.56853.29 ± 5.67879.36 ± 24.80055.90 ± 22.507
Visit 4 (Day 10) Change from baseline3.32 ± 7.16312.71 ± 9.48638.14 ± 22.78127.05 ± 22.700
Visit 5 (Day 17) Platelet count40.10 ± 9.91641.33 ± 4.80355.73 ± 14.82641.80 ± 16.578
Visit 5 (Day 17) Change from baseline0.40 ± 5.2431.75 ± 3.40214.50 ± 11.87412.95 ± 12.857
Visit 6 (Day 35) Platelet count41.50 ± 10.84539.67 ± 5.57441.36 ± 8.26231.44 ± 8.353
Visit 6 (Day 35) Change from baseline1.80 ± 4.6140.08 ± 1.6860.14 ± 8.3822.33 ± 4.265
Statistical analysis
  • Placebo (60 mg) vs Avatrombopag (20 mg) · Wilcoxon (Mann-Whitney) · p = 0.296 (P-value is based on Wilcoxon rank sum test at a two-sided significance level of α = 0.05 for each avatrombopag treatment group vs. placebo.)
  • Placebo (60 mg) vs Avatrombopag (40 mg) · Wilcoxon (Mann-Whitney) · p = 0.070 (P-value is based on Wilcoxon rank sum test at a two-sided significance level of α = 0.05 for each avatrombopag treatment group vs. placebo.)
  • Placebo (60 mg) vs Avatrombopag (60 mg) · Wilcoxon (Mann-Whitney) · p = 0.138 (P-value is based on Wilcoxon rank sum test at a two-sided significance level of α = 0.05 for each avatrombopag treatment group vs. placebo.)
  • Placebo (60 mg) vs Avatrombopag (20 mg) · Wilcoxon (Mann-Whitney) · p = 0.012 (P-value is based on Wilcoxon rank sum test at a two-sided significance level of α = 0.05 for each avatrombopag treatment group vs. placebo.)
  • Placebo (60 mg) vs Avatrombopag (40 mg) · Wilcoxon (Mann-Whitney) · p = 0.001 (P-value is based on Wilcoxon rank sum test at a two-sided significance level of α = 0.05 for each avatrombopag treatment group vs. placebo.)
  • Placebo (60 mg) vs Avatrombopag (60 mg) · Wilcoxon (Mann-Whitney) · p = 0.001 (P-value is based on Wilcoxon rank sum test at a two-sided significance level of α = 0.05 for each avatrombopag treatment group vs. placebo.)
  • Placebo (60 mg) vs Avatrombopag (20 mg) · Wilcoxon (Mann-Whitney) · p = 0.624 (P-value is based on Wilcoxon rank sum test at a two-sided significance level of α = 0.05 for each avatrombopag treatment group vs. placebo.)
  • Placebo (60 mg) vs Avatrombopag (40 mg) · Wilcoxon (Mann-Whitney) · p = 0.009 (P-value is based on Wilcoxon rank sum test at a two-sided significance level of α = 0.05 for each avatrombopag treatment group vs. placebo.)
  • Placebo (60 mg) vs Avatrombopag (60 mg) · Wilcoxon (Mann-Whitney) · p = 0.010 (P-value is based on Wilcoxon rank sum test at a two-sided significance level of α = 0.05 for each avatrombopag treatment group vs. placebo.)
  • Placebo (60 mg) vs Avatrombopag (20 mg) · Wilcoxon (Mann-Whitney) · p = 0.154 (P-value is based on Wilcoxon rank sum test at a two-sided significance level of α = 0.05 for each avatrombopag treatment group vs. placebo.)
  • Placebo (60 mg) vs Avatrombopag (40 mg) · Wilcoxon (Mann-Whitney) · p = 0.216 (P-value is based on Wilcoxon rank sum test at a two-sided significance level of α = 0.05 for each avatrombopag treatment group vs. placebo.)
  • Placebo (60 mg) vs Avatrombopag (60 mg) · Wilcoxon (Mann-Whitney) · p = 0.901 (P-value is based on Wilcoxon rank sum test at a two-sided significance level of α = 0.05 for each avatrombopag treatment group vs. placebo.)
Other pre-specifiedNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Safety assessments consisted of monitoring and recording all AEs and SAEs, regular monitoring of hematology, blood chemistry, and urine values; periodic measurement of vital signs and electrocardiograms; physical examinations; and Doppler sonography. AE severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death related to the AE. All AEs graded as 4 or 5 were considered to be serious. A treatment-emergent adverse event (TEAE) was defined as an AE that started on or after the date of first dose of study drug, up to 30 days after the last dose of study drug. For each category, a participant with two or more adverse events in that category was counted only once. Treatment-related TEAEs were considered by the investigator to be possibly or probably related to study drug or TEAEs with a missing causality.

Time frame:
From the date of first dose of study drug up to 30 days after the last dose of the study drug, up to approximately 10 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPlaceboAvatrombopag 20-mgAvatrombopag 40-mgAvatrombopag 60-mg
All TEAEs8483
Treatment-related TEAEs0220
Serious TEAEs0000
TEAEs leading to study drug dose adjustment0000
TEAEs leading to study drug withdrawal0000
TEAEs leading to study drug dose reduction0000
TEAEs leading to study drug dose interruption0000
Other pre-specifiedNumber of Participants With Treatment-emergent Markedly Abnormal Laboratory Value (TEMAV) for Haematology
Time frame:
From the date of Screening until the date of last dose of study drug plus 30 days (Approximately 10 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Markedly Abnormal Laboratory Value (TEMAV) for Haematology
ParticipantsPlaceboAvatrombopag 20-mgAvatrombopag 40-mgAvatrombopag 60-mg
Hemoglobin1001
Leukocytes4420
Alkaline phosphatase (ALP)1000
Alanine aminotransferase (ALT)0001
Bilirubin1122
Gamma-glutamyl transferase (γ-GTP)0001
Calcium0002
Albumin1110
Glucose3221
Triglycerides9010
Aspartate aminotransferase (AST)0101
Other pre-specifiedNumber of Participants With Clinically Significant Findings in Laboratory Values for Serum
Time frame:
From the date of Screening until the date of last dose of study drug plus 30 days (Approximately 10 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Findings in Laboratory Values for Serum
ParticipantsPlaceboAvatrombopag 20-mgAvatrombopag 40-mgAvatrombopag 60-mg
Number of Participants With Clinically Significant Findings in Laboratory Values for Serum0000
Other pre-specifiedNumber of Participants With Clinically Significant Findings in Laboratory Values for Urinalysis
Time frame:
From the date of Screening until the date of last dose of study drug plus 30 days (Approximately 10 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Findings in Laboratory Values for Urinalysis
ParticipantsPlaceboAvatrombopag 20-mgAvatrombopag 40-mgAvatrombopag 60-mg
Number of Participants With Clinically Significant Findings in Laboratory Values for Urinalysis0000
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in Vital Sign Values
Time frame:
From the date of Screening until the date of last dose of study drug plus 30 days (Approximately 10 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Vital Sign Values
ParticipantsPlaceboAvatrombopag 20-mgAvatrombopag 40-mgAvatrombopag 60-mg
Number of Participants With Clinically Significant Change From Baseline in Vital Sign Values0000
Other pre-specifiedNumber of Participants With Markedly Abnormal Electrocardiographs
Time frame:
From the date of Screening until the date of last dose of study drug plus 30 days (Approximately 10 months)
Reported as:
Count of participants · Participants
Number of Participants With Markedly Abnormal Electrocardiographs
ParticipantsPlaceboAvatrombopag 20-mgAvatrombopag 40-mgAvatrombopag 60-mg
Number of Participants With Markedly Abnormal Electrocardiographs0000

Adverse events

Collected over From the date of first dose of study drug up to 30 days after the last dose of the study drug, up to approximately 10 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (60 mg)0/11 (0%)0/11 (0%)8/11 (72.7%)
Avatrombopag (20 mg)0/7 (0%)0/7 (0%)4/7 (57.1%)
Avatrombopag (40 mg)0/11 (0%)0/11 (0%)8/11 (72.7%)
Avatrombopag (60 mg)0/10 (0%)0/10 (0%)3/10 (30%)
Most frequent other events
Showing 10 of 32
Most frequent other events
EventPlacebo (60 mg)Avatrombopag (20 mg)Avatrombopag (40 mg)Avatrombopag (60 mg)
Post Procedural ComplicationInjury, poisoning and procedural complications1/112/72/110/10
ConstipationGastrointestinal disorders0/110/72/110/10
Post Embolisation SyndromeInjury, poisoning and procedural complications0/110/72/111/10
Conjunctival HaemorrhageEye disorders0/111/70/110/10
Abdominal DiscomfortGastrointestinal disorders1/111/70/110/10
DiarrhoeaGastrointestinal disorders1/111/70/111/10
Injection Site ReactionGeneral disorders0/111/70/110/10
Vessel Puncture Site HaematomaGeneral disorders0/111/70/110/10
Acute SinusitisInfections and infestations0/111/70/110/10
Alanine Aminotransferase IncreasedInvestigations0/111/70/110/10

Baseline characteristics

Full Analysis Set (FAS): The FAS was the group of randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Placebo (60 mg)Avatrombopag (20 mg)Avatrombopag (40 mg)Avatrombopag (60 mg)Total
Mean71.1 ± 8.4964.6 ± 8.4264.6 ± 9.5962.1 ± 7.3265.8 ± 8.92
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (60 mg)Avatrombopag (20 mg)Avatrombopag (40 mg)Avatrombopag (60 mg)Total
Female415313
Male766726
08

Study locations

14 sites
  • Matsuyama, Ehime, Japan
  • Iizuka, Fukuoka, Japan
  • Kitakyushu, Fukuoka, Japan
  • Kurume, Fukuoka, Japan
  • Kure, Hiroshima, Japan
  • Sapporo, Hokkaido, Japan
  • Sagamihara, Kanagawa, Japan
  • Ikeda, Osaka, Japan
  • Takatsuki, Osaka, Japan
  • Minato-Ku, Tokyo, Japan
  • Fukuoka, Japan
  • Kumamoto, Japan
  • Osaka, Japan
  • Yamanashi, Japan
09

References and documents

Publications

  • Eguchi Y, Takahashi H, Mappa S, Santagostino E. Phase 2 study of avatrombopag in Japanese patients with chronic liver disease and thrombocytopenia. Hepatol Res. 2022 Apr;52(4):371-380. doi: 10.1111/hepr.13755. Epub 2022 Feb 21. PubMed 35134259 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in Apr 2015, 9 months.

Results were first posted in Feb 2019, 3 years 10 months after primary completion.

Of 54 phase 2 interventional studies under Thrombocytopenia, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2014
First posted
Aug 28, 2014
StartActual
Jul 2014
Primary completionActual
Apr 1, 2015
CompletionActual
Apr 1, 2015
Results first posted
Feb 28, 2019
Last update
Feb 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02227693
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Aug 28, 2014
Start date
Jul 2014
Primary completion
Apr 1, 2015
Completion
Apr 1, 2015
Results posted
Feb 28, 2019
Last update
Feb 28, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avatrombopag

Start the discussion